Protocol
11-074
Full Title
A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients with Colorectal Cancer
Purpose
The purpose of this study is to find the highest dose of a new drug that can be given safely to patients with metastatic colorectal cancer. The investigational agent, IMMU-130, has two parts: the drug SN-38 and an antibody which will take the drug directly to colorectal cancer cells, where it binds to a specific protein called CEA.
Investigator
Eligibility
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have metastatic colorectal cancer that persists despite at least one prior regimen of irinotecan-containing chemotherapy.
- At least 4 weeks must have passed since completion of prior therapy and entry into the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact the office of Dr. Neil H. Segal at 646-888-4187.
Disease(s)
Colorectal Cancer
Colorectal Cancer: Colon Cancer
Locations
Related Diseases
